Droxinavir - Misplaced Pages

Droxinavir
Names

IUPAC name 3-tert-butyl-1-butyramido]-2-hydroxy-4-phenylbutyl-1-isopentylurea
Other names SC 55389A
Identifiers
CAS Number	159910-86-8
3D model (JSmol)	Interactive image
ChEMBL	ChEMBL2110878
ChemSpider	409165
PubChem CID	70683043
UNII	3CF21QCB9J
CompTox Dashboard (EPA)	DTXSID30166769
InChI InChI=1S/C29H51N5O4/c1-19(2)15-22(26(37)34-29(6,7)8)31-17-23(35)21(16-20-13-11-10-12-14-20)32-27(38)25(28(3,4)5)33-24(36)18-30-9/h10-14,19,21-23,25,30-31,35H,15-18H2,1-9H3,(H,32,38)(H,33,36)(H,34,37)/t21-,22?,23+,25+/m0/s1Key: PLQLXAKSONXQOQ-XCZUPJPTSA-N
SMILES CC(C)CC(C(=O)NC(C)(C)C)NCC(C(CC1=CC=CC=C1)NC(=O)C(C(C)(C)C)NC(=O)CNC)O
Properties
Chemical formula	C₂₉H₅₁N₅O₄
Molar mass	533.75 g·mol
Except where otherwise noted, data are given for materials in their standard state (at 25 °C , 100 kPa). N (what is ?) Infobox references

Chemical compound

Droxinavir (also known as SC 55389A) was an experimental protease inhibitor researched by Pharmacia as a treatment for HIV infection. Its research and development was discontinued on March 06, 1995.

References

"Drug Profile: Droxinavir". AdisInsight. Adis International Ltd, part of Springer Science+Business Media. Retrieved 23 November 2015.

Antiviral drugs: antiretroviral drugs used against HIV (primarily J05)

Capsid inhibitors

Lenacapavir (LEN)

Entry/fusion inhibitors
(Discovery and development)

Integrase inhibitors
(Integrase strand transfer inhibitors (INSTI))

Maturation inhibitors

Protease Inhibitors (PI)
(Discovery and development)

1 generation	Amprenavir (APV) Fosamprenavir (FPV) Indinavir (IDV) Lopinavir (LPV) Nelfinavir (NFV) Ritonavir (RTV) Saquinavir (SQV)
2 generation	Atazanavir (ATV)° Darunavir (DRV)° Tipranavir (TPV) TMC-310911

Reverse-transcriptase
inhibitors (RTIs)

Nucleoside and
nucleotide (NRTI)

Non-nucleoside (NNRTI)
(Discovery and development)

1 generation	Efavirenz (EFV) Nevirapine (NVP) Delavirdine (DLV)
2 generation	diarylpyrimidines Dapivirine (DPV) Etravirine (ETR) Rilpivirine (RPV) Doravirine (DOR) Elsulfavirine (ESV)

Combined formulations

Pharmacokinetic boosters

Experimental agents

Uncoating inhibitors	TRIM5alpha (gene)
Transcription inhibitors	Tat antagonists
Translation inhibitors	Trichosanthin
BNAbs	Elipovimab
Other	Abzyme BIT225 Calanolide A Ceragenin Cyanovirin-N Diarylpyrimidines Epigallocatechin gallate (EGCG) Foscarnet Fosdevirine Griffithsin Hydroxycarbamide KP-1461 Miltefosine Portmanteau inhibitors Scytovirin Seliciclib Synergistic enhancers Tre recombinase Zinc finger protein transcription factor
Failed agents	Aplaviroc Atevirdine Brecanavir Capravirine Dexelvucitabine Droxinavir Lasinavir Emivirine Lersivirine Lodenosine Loviride Mozenavir Palinavir Telinavir

WHO-EM
Withdrawn from market
Clinical trials:
- Phase III
- Never to phase III

°DHHS recommended initial regimen options. Formerly or rarely used agent.

This antiinfective drug article is a stub. You can help Misplaced Pages by expanding it.

Categories: